الفهرس Only 14 pages are availabe for public view
 |  | from | 92 |  |  |
| | | from | 92 | | |
Abstract
Allergy plays a central role in clinical practice of otolaryngology. Around 50% of patient’s complaints encountered by ear, nose and throat specialists have an allergic components and inhalant allergy particularly prevalent.
The World Health Organization acknowledged that allergen-specific immunotherapy is a cornerstone in the management of respiratory allergy as it affects the immunological response towards allergen at its earliest stages.
In fact, immunotherapy not only reduces the symptoms load in the short term, but also has a favourable impact on natural history of allergic disease (the so-called allergy march).
Allergy march is defined as the progression from food allergy and atopic dermatitis (in infancy) to rhinitis and then asthma.
These achievements have been established initially with Subcutaneous Immunotherapy (SCIT) and subsequently extended to Sublingual Immunotherapy (SLIT).
Both forms of treatment can prevent the onset of asthma in subjects with allergic rhinitis.
The natural history of allergic subjects with nasal disease is suitable for therapeutic modification, even in cases in which initially only surgical treatment could remove patient-specific complaint particularly. These depend on nasal blockage.
In fact, subjects undergoing surgery related to anatomical problems such as septal deformity or turbinate hypertrophy of polyp disease, could have a diminished probability of subsequent surgical intervention if allergy is addressed as a contributing factor to the nasal disease itself.